XELJANZ / XELJANZ XR Clinical Studies

(tofacitinib)

14 CLINICAL STUDIES

14.1 Rheumatoid Arthritis

The XELJANZ clinical development program included six confirmatory trials. Although other doses have been studied, the recommended dose of XELJANZ is 5 mg twice daily. XELJANZ 10 mg twice daily is not recommended for the treatment of rheumatoid arthritis [see Dosage and Administration (2.2)].

Confirmatory Trials

Study RA-I (NCT00814307) was a 6-month monotherapy trial in which 610 patients with moderate to severe active rheumatoid arthritis who had an inadequate response to a DMARD (nonbiologic or biologic) received XELJANZ 5 or 10 mg twice daily or placebo. At the Month 3 visit, all patients randomized to placebo treatment were advanced in a blinded fashion to a second predetermined treatment of XELJANZ 5 or 10 mg twice daily. The primary endpoints at Month 3 were the proportion of patients who achieved an ACR20 response, changes in Health Assessment Questionnaire – Disability Index (HAQ-DI), and rates of Disease Activity Score DAS28-4(ESR) less than 2.6.

Study RA-II (NCT00856544) was a 12-month trial in which 792 patients with moderate to severe active rheumatoid arthritis who had an inadequate response to a nonbiologic DMARD received XELJANZ 5 or 10 mg twice daily or placebo added to background DMARD treatment (excluding potent immunosuppressive treatments such as azathioprine or cyclosporine). At the Month 3 visit, nonresponding patients were advanced in a blinded fashion to a second predetermined treatment of XELJANZ 5 or 10 mg twice daily. At the end of Month 6, all placebo patients were advanced to their second predetermined treatment in a blinded fashion. The primary endpoints were the proportion of patients who achieved an ACR20 response at Month 6, changes in HAQ-DI at Month 3, and rates of DAS28-4(ESR) less than 2.6 at Month 6.

Study RA-III (NCT00853385) was a 12-month trial in 717 patients with moderate to severe active rheumatoid arthritis who had an inadequate response to MTX. Patients received XELJANZ 5 or 10 mg twice daily, adalimumab 40 mg subcutaneously every other week, or placebo added to background MTX. Placebo patients were advanced as in Study II. The primary endpoints were the proportion of patients who achieved an ACR20 response at Month 6, HAQ-DI at Month 3, and DAS28-4(ESR) less than 2.6 at Month 6.

Study RA-IV (NCT00847613) was a 2-year trial with a planned analysis at 1 year in which 797 patients with moderate to severe active rheumatoid arthritis who had an inadequate response to MTX received XELJANZ 5 or 10 mg twice daily or placebo added to background MTX. Placebo patients were advanced as in Study II. The primary endpoints were the proportion of patients who achieved an ACR20 response at Month 6, mean change from baseline in van der Heijde-modified total Sharp Score (mTSS) at Month 6, HAQ-DI at Month 3, and DAS28-4(ESR) less than 2.6 at Month 6.

Study RA-V (NCT00960440) was a 6-month trial in which 399 patients with moderate to severe active rheumatoid arthritis who had an inadequate response to at least one approved TNF blocking biologic agent received XELJANZ 5 or 10 mg twice daily or placebo added to background MTX. At the Month 3 visit, all patients randomized to placebo treatment were advanced in a blinded fashion to a second predetermined treatment of XELJANZ 5 or 10 mg twice daily. The primary endpoints at Month 3 were the proportion of patients who achieved an ACR20 response, HAQ-DI, and DAS28-4(ESR) less than 2.6.

Study RA-VI (NCT01039688) was a 2-year monotherapy trial with a planned analysis at 1 year in which 952 MTX-naïve patients with moderate to severe active rheumatoid arthritis received XELJANZ 5 or 10 mg twice daily or MTX dose-titrated over 8 weeks to 20 mg weekly. The primary endpoints were mean change from baseline in van der Heijde-modified Total Sharp Score (mTSS) at Month 6 and the proportion of patients who achieved an ACR70 response at Month 6.

Clinical Response

The percentages of XELJANZ-treated patients achieving ACR20, ACR50, and ACR70 responses in Studies RA-I, IV, and V are shown in Table 9. Similar results were observed with Studies RA-II and III. In trials RA-I through V, patients treated with 5 mg twice daily XELJANZ had higher ACR20, ACR50, and ACR70 response rates versus placebo, with or without background DMARD treatment, at Month 3 and Month 6. Higher ACR20 response rates were observed within 2 weeks compared to placebo. In the 12-month trials, ACR response rates in XELJANZ-treated patients were consistent at 6 and 12 months.

Table 9: Proportion of Patients with an ACR Response
	Percent of Patients
	Monotherapy in Nonbiologic or Biologic DMARD Inadequate Responders*		MTX Inadequate Responders†		TNF Blocker Inadequate Responders‡
	Study I		Study IV		Study V
N§	PBO	XELJANZ 5 mg Twice Daily	PBO + MTX	XELJANZ 5 mg Twice Daily + MTX	PBO + MTX	XELJANZ 5 mg Twice Daily + MTX
	122	243	160	321	132	133
* Inadequate response to at least one DMARD (biologic or nonbiologic) due to lack of efficacy or toxicity. † Inadequate response to MTX defined as the presence of sufficient residual disease activity to meet the entry criteria. ‡ Inadequate response to a least one TNF blocker due to lack of efficacy and/or intolerance. § N is number of randomized and treated patients. ¶ NA Not applicable, as data for placebo treatment is not available beyond 3 months in Studies I and V due to placebo advancement.
ACR20
Month 3	26%	59%	27%	55%	24%	41%
Month 6	NA¶	69%	25%	50%	NA	51%
ACR50
Month 3	12%	31%	8%	29%	8%	26%
Month 6	NA	42%	9%	32%	NA	37%
ACR70
Month 3	6%	15%	3%	11%	2%	14%
Month 6	NA	22%	1%	14%	NA	16%

In Study RA-IV, a greater proportion of patients treated with XELJANZ 5 mg twice daily plus MTX achieved a low level of disease activity as measured by a DAS28-4(ESR) less than 2.6 at 6 months compared to those treated with MTX alone (Table 10).

Table 10: Proportion of Patients with DAS28-4(ESR) Less Than 2.6 with Number of Residual Active Joints
	Study IV
DAS28-4(ESR) Less Than 2.6	Placebo + MTX	XELJANZ 5 mg Twice Daily + MTX
	160	321
Proportion of responders at Month 6 (n)	1% (2)	6% (19)
Of responders, proportion with 0 active joints (n)	50% (1)	42% (8)
Of responders, proportion with 1 active joint (n)	0	5% (1)
Of responders, proportion with 2 active joints (n)	0	32% (6)
Of responders, proportion with 3 or more active joints (n)	50% (1)	21% (4)

The results of the components of the ACR response criteria for Study RA-IV are shown in Table 11. Similar results were observed for XELJANZ in Studies RA-I, II, III, V, and VI.

Table 11: Components of ACR Response at Month 3
	Study IV
	XELJANZ 5 mg Twice Daily + MTX		Placebo + MTX
	N=321		N=160
Component (mean) *	Baseline	Month 3*	Baseline	Month 3*
* Data shown is mean (Standard Deviation) at Month 3. † Visual analog scale: 0 = best, 100 = worst. ‡ Health Assessment Questionnaire Disability Index: 0 = best, 3 = worst; 20 questions; categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.
Number of tender joints (0–68)	24 (14)	13 (14)	23 (13)	18 (14)
Number of swollen joints (0–66)	14 (8)	6 (8)	14 (9)	10 (9)
Pain†	58 (23)	34 (23)	55 (24)	47 (24)
Patient global assessment†	58 (24)	35 (23)	54 (23)	47 (24)
Disability index (HAQ-DI)‡	1.41 (0.68)	0.99 (0.65)	1.32 (0.67)	1.19 (0.68)
Physician global assessment†	59 (16)	30 (19)	56 (18)	43 (22)
CRP (mg/L)	15.3 (19.0)	7.1 (19.1)	13.7 (14.9)	14.6 (18.7)

The percent of ACR20 responders by visit for Study RA-IV is shown in Figure 4. Similar responses were observed for XELJANZ in Studies RA-I, II, III, V, and VI.

Figure 4: Percentage of ACR20 Responders by Visit for Study RA-IV

Radiographic Response

Two studies were conducted to evaluate the effect of XELJANZ on structural joint damage. In Study RA-IV and Study RA-VI, progression of structural joint damage was assessed radiographically and expressed as change from baseline in mTSS and its components, the erosion score and joint space narrowing score, at Months 6 and 12. The proportion of patients with no radiographic progression (mTSS change less than or equal to 0) was also assessed.

In Study RA-IV, XELJANZ 5 mg twice daily reduced the mean progression of structural damage (not statistically significant) as shown in Table 12. Analyses of erosion and joint space narrowing scores were consistent with the overall results.

In the placebo plus MTX group, 74% of patients experienced no radiographic progression at Month 6 compared to 84% of patients treated with XELJANZ plus MTX 5 mg twice daily.

In Study RA-VI, XELJANZ monotherapy inhibited the progression of structural damage compared to MTX at Months 6 and 12 as shown in Table 12. Analyses of erosion and joint space narrowing scores were consistent with the overall results.

In the MTX group, 55% of patients experienced no radiographic progression at Month 6 compared to 73% of patients treated with XELJANZ 5 mg twice daily.

Table 12: Radiographic Changes at Months 6 and 12
* SD = Standard Deviation † Difference between least squares means XELJANZ minus placebo or MTX (95% CI = 95% confidence interval) ‡ Month 6 and Month 12 data are mean change from baseline.
	Study IV
	Placebo N=139 Mean (SD)*	XELJANZ 5 mg Twice Daily N=277 Mean (SD) *	XELJANZ 5 mg Twice Daily Mean Difference from Placebo† (CI)
mTSS‡
Baseline	33 (42)	31 (48)	-
Month 6	0.5 (2.0)	0.1 (1.7)	-0.3 (-0.7, 0.0)
	Study VI
	MTX N=166 Mean (SD)*	XELJANZ 5 mg Twice Daily N=346 Mean (SD) *	XELJANZ 5 mg Twice Daily Mean Difference from MTX† (CI)
mTSS‡
Baseline	17 (29)	20 (40)	-
Month 6	0.8 (2.7)	0.2 (2.3)	-0.7 (-1.0, -0.3)
Month 12	1.3 (3.7)	0.4 (3.0)	-0.9 (-1.4, -0.4)

Physical Function Response

Improvement in physical functioning was measured by the HAQ-DI. Patients receiving XELJANZ 5 mg twice daily demonstrated greater improvement from baseline in physical functioning compared to placebo at Month 3.

The mean (95% CI) difference from placebo in HAQ-DI improvement from baseline at Month 3 in Study RA-III was -0.22 (-0.35, -0.10) in patients receiving 5 mg XELJANZ twice daily. Similar results were obtained in Studies RA-I, II, IV and V. In the 12-month trials, HAQ-DI results in XELJANZ-treated patients were consistent at 6 and 12 months.

Other Health-Related Outcomes

General health status was assessed by the Short Form health survey (SF-36). In Studies RA-I, IV, and V, patients receiving XELJANZ 5 mg twice daily demonstrated greater improvement from baseline compared to placebo in physical component summary (PCS), mental component summary (MCS) scores and in all 8 domains of the SF-36 at Month 3.

14.2 Psoriatic Arthritis

The XELJANZ clinical development program to assess efficacy and safety included 2 multicenter, randomized, double-blind, placebo-controlled confirmatory trials in 816 patients 18 years of age and older (PsA-I and PsA-II). Although other doses have been studied, the recommended dose of XELJANZ is 5 mg twice daily. XELJANZ 10 mg twice daily is not recommended for the treatment of psoriatic arthritis [see Dosage and Administration (2.2)]. All patients had active psoriatic arthritis for at least 6 months based upon the Classification Criteria for Psoriatic Arthritis (CASPAR), at least 3 tender/painful joints and at least 3 swollen joints, and active plaque psoriasis. Patients randomized and treated across the 2 clinical trials represented different psoriatic arthritis subtypes at screening, including <5 joints or asymmetric involvement (21%), ≥5 joints involved (90%), distal interphalangeal (DIP) joint involvement (61%), arthritis mutilans (8%), and spondylitis (19%). Patients in these clinical trials had a diagnosis of psoriatic arthritis for a mean (SD) of 7.7 (7.2) years. At baseline, 80% and 53% of patients had enthesitis and dactylitis, respectively. At baseline, all patients were required to receive treatment with a stable dose of a nonbiologic DMARD (79% received methotrexate, 13% received sulfasalazine, 7% received leflunomide, 1% received other nonbiologic DMARDs). In both clinical trials, the primary endpoints were the ACR20 response and the change from baseline in HAQ-DI at Month 3.

Study PsA-I was a 12-month clinical trial in 422 patients who had an inadequate response to a nonbiologic DMARD (67% and 33% were inadequate responders to 1 nonbiologic DMARD and ≥2 nonbiologic DMARDs, respectively) and who were naïve to treatment with a TNF blocker. Patients were randomized in a 2:2:2:1:1 ratio to receive XELJANZ 5 mg twice daily, XELJANZ 10 mg twice daily, adalimumab 40 mg subcutaneously once every 2 weeks, placebo to XELJANZ 5 mg twice daily treatment sequence, or placebo to XELJANZ 10 mg twice daily treatment sequence, respectively; study drug was added to background nonbiologic DMARD treatment. At the Month 3 visit, all patients randomized to placebo treatment were advanced in a blinded fashion to a predetermined XELJANZ dose of 5 mg or 10 mg twice daily. Study PsA-I was not designed to demonstrate noninferiority or superiority to adalimumab.

Study PsA-II was a 6-month clinical trial in 394 patients who had an inadequate response to at least 1 approved TNF blocker (66%, 19%, and 15% were inadequate responders to 1 TNF blocker, 2 TNF blockers and ≥3 TNF blockers, respectively). Patients were randomized in a 2:2:1:1 ratio to receive XELJANZ 5 mg twice daily, XELJANZ 10 mg twice daily, placebo to XELJANZ 5 mg twice daily treatment sequence, or placebo to XELJANZ 10 mg twice daily treatment sequence, respectively; study drug was added to background nonbiologic DMARD treatment. At the Month 3 visit, placebo patients were advanced in a blinded fashion to a predetermined XELJANZ dose of 5 mg or 10 mg twice daily as in Study PsA-I.

Clinical Response

At Month 3, patients treated with XELJANZ 5 mg twice daily had higher (p≤0.05) response rates versus placebo for ACR20, ACR50, and ACR70 in Study PsA-I and for ACR20 and ACR50 in Study PsA-II; ACR70 response rates were also higher for XELJANZ 5 mg twice daily versus placebo in Study PsA-II, although the differences versus placebo were not statistically significant (p>0.05) (Tables 13 and 14).

Table 13: Proportion of Patients with an ACR Response in Study PsA-I* [Nonbiologic DMARD Inadequate Responders (TNF Blocker-Naïve)]
Treatment Group	Placebo	XELJANZ 5 mg Twice Daily
N†	105	107
	Response Rate	Response Rate	Difference (%) 95% CI from Placebo
Subjects with missing data were treated as non-responders.
* Subjects received one concomitant nonbiologic DMARD. † N is number of randomized and treated patients.
Month 3
ACR20	33%	50%	17.1 (4.1, 30.2)
ACR50	10%	28%	18.5 (8.3, 28.7)
ACR70	5%	17%	12.1 (3.9, 20.2)

Table 14: Proportion of Patients with an ACR Response in Study PsA-II* (TNF Blocker Inadequate Responders)
Treatment Group	Placebo	XELJANZ 5 mg Twice Daily
N†	131	131
	Response Rate	Response Rate	Difference (%) 95% CI from Placebo
Subjects with missing data were treated as non-responders.
* Subjects received one concomitant nonbiologic DMARD. † N is number of randomized and treated patients.
Month 3
ACR20	24%	50%	26.0 (14.7, 37.2)
ACR50	15%	30%	15.3 (5.4, 25.2)
ACR70	10%	17%	6.9 (-1.3, 15.1)

Improvements from baseline in the ACR response criteria components for both studies are shown in Table 15.

Table 15: Components of ACR Response at Baseline and Month 3 in Studies PsA-I and PsA-II
	Nonbiologic DMARD Inadequate Responders (TNF Blocker-Naïve)		TNF Blocker Inadequate Responders
	Study PsA-I*		Study PsA-II*
Treatment Group	Placebo	XELJANZ 5 mg Twice Daily	Placebo	XELJANZ 5 mg Twice Daily
N at Baseline	105	107	131	131
* Subjects received one concomitant nonbiologic DMARD. † Data shown are mean value at baseline and at Month 3. ‡ Visual analog scale (VAS): 0 = best, 100 = worst. § HAQ-DI = Health Assessment Questionnaire – Disability Index: 0 = best, 3 = worst; 20 questions; categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.
ACR Component†
Number of tender/painful joints (0–68)
Baseline	20.6	20.5	19.8	20.5
Month 3	14.6	12.2	15.1	11.5
Number of swollen joints (0–66)
Baseline	11.5	12.9	10.5	12.1
Month 3	7.1	6.3	7.7	4.8
Patient assessment of arthritis pain‡
Baseline	53.2	55.7	54.9	56.4
Month 3	44.7	34.7	48.0	36.1
Patient global assessment of arthritis‡
Baseline	53.9	54.7	55.8	57.4
Month 3	44.4	35.5	49.2	36.9
HAQ-DI§
Baseline	1.11	1.16	1.25	1.26
Month 3	0.95	0.81	1.09	0.88
Physician's Global Assessment of Arthritis‡
Baseline	53.8	54.6	53.7	53.5
Month 3	35.4	29.5	36.4	27.0
CRP (mg/L)
Baseline	10.4	10.5	12.1	13.8
Month 3	8.6	4.0	11.4	7.7

The percentage of ACR20 responders by visit for Study PsA-I is shown in Figure 5. Similar responses were observed in Study PsA-II. In both studies, improvement in ACR20 response on XELJANZ was observed at the first visit after baseline (Week 2).

BID=twice daily; SE=standard error.
Subjects with missing data were treated as non-responders.

*: Subjects received one concomitant nonbiologic DMARD.

Figure 5: Percentage of ACR20 Responders by Visit Through Month 3 in Study PsA-I*

In patients with active psoriatic arthritis evidence of benefit in enthesitis and dactylitis was observed with XELJANZ treatment.

Physical Function

Improvement in physical functioning was measured by the HAQ-DI. Patients receiving XELJANZ 5 mg twice daily demonstrated significantly greater improvement (p ≤0.05) from baseline in physical functioning compared to placebo at Month 3 (Table 16).

Table 16: Change from Baseline in HAQ-DI in Studies PsA-I and PsA-II
	Least Squares Mean Change from Baseline In HAQ-DI at Month 3
	Nonbiologic DMARD Inadequate Responders* (TNF Blocker-Naïve)		TNF Blocker Inadequate Responders†
	Study PsA-I‡		Study PsA-II‡
Treatment Group	Placebo	XELJANZ 5 mg Twice Daily	Placebo	XELJANZ 5 mg Twice Daily
N§	104	107	131	129
* Inadequate response to at least one nonbiologic DMARD due to lack of efficacy and/or intolerability. † Inadequate response to at least one TNF blocker due to lack of efficacy and/or intolerability. ‡ Subjects received one concomitant nonbiologic DMARD. § N is the total number of subjects in the statistical analysis.
LSM Change from Baseline	-0.18	-0.35	-0.14	-0.39
Difference from Placebo (95% CI)	-	-0.17 (-0.29, -0.05)	-	-0.25 (-0.38, -0.13)

In Study PsA-I, the HAQ-DI responder rate (response defined as having improvement from baseline of ≥0.35) at Month 3 was 53% in patients receiving XELJANZ 5 mg twice daily and 31% in patients receiving placebo. Similar responses were observed in Study PsA-II.

Other Health-Related Outcomes

General health status was assessed by the Short Form health survey (SF-36). In Studies PsA-I and PsA-II, patients receiving XELJANZ 5 mg twice daily had greater improvement from baseline compared to placebo in Physical Component Summary (PCS) score, but not in Mental Component Summary (MCS) score at Month 3. Patients receiving XELJANZ 5 mg twice daily reported consistently greater improvement relative to placebo in the domains of Physical Functioning, Bodily Pain, Vitality, and Social Functioning, but not in Role-Physical, General Health, Role-Emotional, or Mental Health.

Radiographic Response

Treatment effect on inhibition of radiographic progression in psoriatic arthritis could not be established from the results of Study PsA-I.

14.3 Ankylosing Spondylitis

The XELJANZ clinical development program to assess the efficacy and safety included one placebo-controlled confirmatory trial (Study AS-I). Patients had active disease as defined by both Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and back pain score (BASDAI question 2) of greater or equal to 4 despite non-steroidal anti-inflammatory drug (NSAID), corticosteroid or disease modifying anti-rheumatic drug (DMARD) therapy.

Confirmatory Trial (Study AS-I)

Study AS-I was a randomized, double-blind, placebo-controlled, 48-week clinical trial in 269 adult patients who had an inadequate response (inadequate clinical response or intolerance) to at least 2 NSAIDs. Patients were randomized and treated with XELJANZ 5 mg twice daily or placebo for 16 weeks of blinded treatment and then all received treatment of XELJANZ 5 mg twice daily for additional 32 weeks. The primary endpoint was to evaluate the proportion of patients who achieved an ASAS20 response at Week 16.

Approximately 7% and 21% of patients used concomitant methotrexate or sulfasalazine, respectively from baseline to Week 16. Twenty-two percent of patients had an inadequate response to 1 or 2 TNF blockers.

Clinical Response

Patients treated with XELJANZ 5 mg twice daily achieved greater improvements in ASAS20 and ASAS40 responses compared to placebo at Week 16 (Table 17). Consistent results were observed in the subgroup of patients who had an inadequate response to TNF blockers for both the ASAS20 (primary endpoint) and ASAS40 (secondary endpoint) at Week 16 (Table 17).

Table 17: ASAS20 and ASAS40 Responses at Week 16, Study AS-I
	Placebo	XELJANZ 5 mg Twice Daily	Difference from Placebo (95% CI)
Abbreviations: CI = confidence interval; TNFi-IR = tumor necrosis factor inhibitor inadequate response.
* type I error-controlled. † p-value <0.0001.
All patients (N)	N=136	N=133
ASAS20 response*, %	29	56	27 (16, 38)†
ASAS40 response*, %	13	41	28 (18, 38)†
TNFi-IR patients (N)	N=30	N=29
ASAS20 response, %	17	41	25 (2, 47)
ASAS40 response, %	7	28	21 (2, 39)

The improvements in the components of the ASAS response and other measures of disease activity were higher in XELJANZ 5 mg twice daily compared to placebo as shown in Table 18.

Table 18: ASAS Components and Other Measures of Disease Activity at Week 16, Study AS-I
	Placebo (N=136)		XELJANZ 5 mg Twice Daily (N=133)
	Baseline (mean)	Week 16 (LSM change from Baseline)*	Baseline (mean)	Week 16 (LSM change from Baseline)*	Difference from Placebo (95% CI)*
LSM = least squares mean.
* Estimates are generated based on a mixed model for repeated measures using both on-treatment and off-treatment data. † Measured on a numerical rating scale with 0 = not active or no pain, 10 = very active or most severe pain. ‡ type I error-controlled. § p < 0.0001. ¶ Bath Ankylosing Spondylitis Functional Index measured on a numerical rating scale with 0 = easy and 10 = impossible. # Inflammation is the mean of two patient-reported stiffness self-assessments in BASDAI. Þ Bath Ankylosing Spondylitis Disease Activity Index total score. ß Bath Ankylosing Spondylitis Metrology Index. à High sensitivity C-reactive protein.
ASAS Components
– Patient Global Assessment of Disease Activity (0–10)†,‡	7.0	-1.0	6.9	-2.5	-1.5 (-2.00, -0.97)§
– Total spinal pain (0–10)†,‡	6.9	-1.1	6.9	-2.6	-1.5 (-2.00, -1.03)§
– BASFI (0–10)¶,‡	5.9	-0.8	5.8	-2.0	-1.2 (-1.64, -0.79)§
– Inflammation (0–10)#,‡	6.8	-1.1	6.6	-2.8	-1.7 (-2.13, -1.18)§
BASDAI ScoreÞ	6.5	-1.2	6.4	-2.6	-1.4 (-1.86, -0.98)§
BASMIß,‡	4.4	-0.1	4.5	-0.6	-0.5 (-0.66, -0.36)§
hsCRPà,‡ (mg/dL)	1.8	-0.1	1.6	-1.1	-0.9 (-1.17, -0.69)§

The percentage of patients achieving ASAS20 response by visit is shown in Figure 6.

Figure 6: ASAS20 Response Over Time Up to Week 16, Study AS-I

SE=standard error.
Patients with missing data were treated as non-responders.

Other Health-Related Outcomes

Patients treated with XELJANZ 5 mg twice daily achieved greater improvements from baseline in Ankylosing Spondylitis Quality of Life (ASQoL) (-4.0 vs -2.0) compared to placebo-treated patients at Week 16.

14.4 Ulcerative Colitis

Induction Trials (Study UC-I [NCT01465763] and Study UC-II [NCT01458951])

In two identical induction trials (UC-I and UC-II), 1139 patients were randomized (598 and 541 patients, respectively) to XELJANZ 10 mg twice daily or placebo with a 4:1 treatment allocation ratio. These trials included adult patients with moderately to severely active UC (total Mayo score of 6 to 12, with an endoscopy subscore of at least 2, and rectal bleeding subscore of at least 1) and who had failed or were intolerant to at least 1 of the following treatments: oral or intravenous corticosteroids, azathioprine, 6-MP or TNF blocker. XELJANZ is indicated for patients who have an inadequate response or intolerance to one or more TNF blockers [see Indications and Usage (1)].

The disease activity was assessed by Mayo scoring index (0 to 12) which consists of four subscores (0 to 3 for each subscore): stool frequency, rectal bleeding, findings on endoscopy, and physician global assessment. An endoscopy subscore of 2 was defined by marked erythema, absent vascular pattern, any friability, and erosions; an endoscopy subscore of 3 was defined by spontaneous bleeding and ulceration.

Patients were permitted to use stable doses of oral aminosalicylates and corticosteroids (prednisone daily dose up to 25 mg equivalent). Concomitant immunosuppressants (oral immunomodulators or biologic therapies) were not permitted for UC patients during these studies.

A total of 52%, 73% and 72% of patients had previously failed or were intolerant to TNF blockers (51% in Study UC-1 and 52% in Study UC-II), corticosteroids (75% in Study UC-I and 71% in Study UC-II), and/or immunosuppressants (74% in Study UC-I and 70% in Study UC-II), respectively.

Oral corticosteroids were received as concomitant treatment for UC by 47% of patients (45% in Study UC-I and 48% in Study UC-II) and 71% were receiving concomitant aminosalicylates as treatment for UC (71% in Study UC-I, and 72% in Study UC-II). The baseline clinical characteristics were generally similar between the XELJANZ treated patients and patients receiving placebo.

The primary endpoint of Study UC-I and Study UC-II was the proportion of patients in remission at Week 8, and the key secondary endpoint was the proportion of patients with improvement of endoscopic appearance of the mucosa at Week 8.

The efficacy results of Study UC-I and Study UC-II based on the centrally read endoscopy results are shown in Table 19.

Table 19: Proportion of Patients Meeting Primary and Key Secondary Efficacy Endpoints at Week 8 (Induction Study UC-I and Study UC-II, Central Endoscopy Read)
CI = Confidence interval; N = number of patients in the analysis set; TNF = tumor necrosis factor
* Remission was defined as clinical remission (a Mayo score ≤2 with no individual subscore >1) and rectal bleeding subscore of 0. † p-value <0.01, ‡ Prior TNF blocker failure was defined in this program as inadequate response, loss of response, or intolerance to TNF blocker therapy. § Patients in this group had failed one or more conventional therapies (corticosteroid, azathioprine, 6-mercaptopurine) but did not have history of prior failure of TNF blocker therapy. ¶ Improvement of endoscopic appearance of the mucosa was defined as Mayo endoscopy subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern). # p-value <0.001.
Study UC-I
Endpoint	Placebo	XELJANZ 10 mg Twice Daily	Treatment Difference versus Placebo (95% CI)
Remission at Week 8*
Total Population	N=122	N=476	10%† (4.3, 16.3)
	8%	18%
With Prior TNF Blocker Failure‡	N=64	N=243
	2%	11%
Without Prior TNF Blocker Failure§	N=58	N=233
	16%	26%
Improvement of endoscopic appearance of the mucosa at Week 8¶
Total Population	N=122	N=476	16%# (8.1, 23.4)
	16%	31%
With Prior TNF Blocker Failure‡	N=64	N=243
	6%	23%
Without Prior TNF Blocker Failure§	N=58	N=233
	26%	40%
Study UC-II
Endpoint	Placebo	XELJANZ 10 mg Twice Daily	Treatment Difference (95% CI)
Remission at Week 8*
Total Population	N=112	N=429	13%# (8.1, 17.9)
	4%	17%
With Prior TNF Blocker Failure‡	N=60	N=222
	0%	12%
Without Prior TNF Blocker Failure§	N=52	N=207
	8%	22%
Improvement of endoscopic appearance of the mucosa at Week 8¶
Total Population	N=112	N-429	17%# (9.5, 24.1)
	12%	28%
With Prior TNF Blocker Failure‡	N=60	N=222
	7%	22%
Without Prior TNF Blocker Failure§	N=52	N=207
	17%	36%

Clinical Response at Week 8

Clinical response was defined as a decrease from baseline in Mayo score of ≥3 points and ≥30%, with an accompanying decrease in the subscore for rectal bleeding of ≥1 point or absolute subscore for rectal bleeding of 0 or 1.

Clinical response was observed in 60% of patients treated with XELJANZ 10 mg twice daily compared to 33% of placebo patients in Study UC-I and 55% compared to 29% in Study UC-II.

Normalization of the Endoscopic Appearance of the Mucosa at Week 8

Normalization of endoscopic appearance of the mucosa was defined as a Mayo endoscopic subscore of 0 and was observed in 7% of patients treated with XELJANZ 10 mg twice daily compared to 2% of placebo patients in both Studies UC-I and UC-II.

Rectal Bleeding and Stool Frequency

Decreases in rectal bleeding and stool frequency subscores were observed as early as Week 2 in patients treated with XELJANZ.

Maintenance Trial (Study UC-III [NCT01458574])

A total of 593 patients who completed the induction trials (UC-I or UC-II) and achieved clinical response were re-randomized with 1:1:1 treatment allocation ratio to XELJANZ 5 mg twice daily, XELJANZ 10 mg twice daily, or placebo for 52 weeks in Study UC-III. XELJANZ 5 mg twice daily is the recommended dosage for maintenance therapy; limit use of XELJANZ 10 mg twice daily beyond induction to those with loss of response and should be used for the shortest duration [see Dosage and Administration (2.3)]. As in the induction trials, patients were permitted to use stable doses of oral aminosalicylates; however, corticosteroid tapering was required upon entrance into this study for patients who were receiving corticosteroids at baseline. Concomitant immunosuppressants (oral immunomodulators or biologic therapies) were not permitted.

At baseline of Study UC-III:

179 (30%) patients were in remission
289 (49%) patients were receiving oral corticosteroids
265 (45%), 445 (75%), and 413 (70%) patients had previously failed or were intolerant to TNF blocker therapy, corticosteroids, and immunosuppressants, respectively.

The primary endpoint was the proportion of patients in remission at Week 52. There were 2 key secondary endpoints: the proportion of patients with improvement of endoscopic appearance at Week 52, and the proportion of patients with sustained corticosteroid-free remission at both Week 24 and Week 52 among patients in remission at baseline of Study UC-III.

The efficacy results of Study UC-III based on the centrally read endoscopy results are summarized in Table 20.

Table 20: Proportion of Patients Meeting Primary and Key Secondary Efficacy Endpoints in Maintenance Study UC-III (Central Endoscopy Read)
				Treatment Difference versus Placebo (95% CI)
Endpoint	Placebo	XELJANZ 5 mg Twice Daily	XELJANZ 10 mg Twice Daily	XELJANZ 5 mg Twice Daily	XELJANZ 10 mg Twice Daily
CI = Confidence interval; N = number of patients in the analysis set; TNF = tumor necrosis factor.
* Remission was defined as clinical remission (a Mayo score ≤2 with no individual subscore >1) and rectal bleeding subscore of 0. † p-value <0.0001. ‡ Prior TNF blocker failure was defined in this program as inadequate response, loss of response, or intolerance to TNF blocker therapy. § Patients in this group had failed one or more conventional therapies (corticosteroid, azathioprine, 6-mercaptopurine) but did not have history of prior failure of TNF blocker therapy. ¶ Improvement of endoscopic appearance of the mucosa was defined as Mayo endoscopy subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern). # Sustained corticosteroid-free remission was defined as being in remission and not taking corticosteroids for at least 4 weeks prior to the visit at both Week 24 and Week 52.
Remission at Week 52*
Total Population	N=198	N=198	N=197	23%† (15.3, 31.2)	30%† (21.4, 37.6)
	11%	34%	41%
With Prior TNF Blocker Failure‡	N=89	N=83	N=93
	11%	24%	37%
Without Prior TNF Blocker Failure§	N=109	N=115	N=104
	11%	42%	44%
Improvement of endoscopic appearance of the mucosa at Week 52¶
Total Population	N=198	N=198	N=197	24%† (16.0, 32.5)	33%† (24.2, 41.0)
	13%	37%	46%
With Prior TNF Blocker Failure‡	N=89	N=83	N=93
	12%	30%	40%
Without Prior TNF Blocker Failure§	N=109	N=115	N=104
	14%	43%	51%
Sustained corticosteroid-free remission at both Week 24 and Week 52 among patients in remission at baseline#
Total Population	N=59	N=65	N=55	30%† (17.4, 43.2)	42%† (27.9, 56.5)
	5%	35%	47%
With Prior TNF Blocker Failure‡	N=21	N=18	N=18
	5%	22%	39%
Without Prior TNF Blocker Failure§	N=38	N=47	N=37
	5%	40%	51%

Maintenance of Clinical Response

Maintenance of clinical response was defined as the proportion of patients who met the definition of clinical response (defined as a decrease from the induction study (UC-I, UC-II) baseline Mayo score of ≥3 points and ≥30%, with an accompanying decrease in the rectal bleeding subscore of ≥1 point or rectal bleeding subscore of 0 or 1) at both Baseline and Week 52 of Study UC-III.

Maintenance of clinical response was observed in 52% in the XELJANZ 5 mg twice daily group and 62% in the XELJANZ 10 mg twice daily group compared to 20% of placebo patients.

Maintenance of Remission (Among Patients in Remission at Baseline)

In the 179 patients who were in remission at baseline of Study UC-III (N = 59 for placebo, N = 65 for XELJANZ 5 mg twice daily, N = 55 for XELJANZ 10 mg twice daily), 46% in the XELJANZ 5 mg twice daily group and 56% in the XELJANZ 10 mg twice daily group maintained remission at Week 52 compared to 10% of placebo patients.

Normalization of the Endoscopic Appearance of the Mucosa

Normalization of endoscopic appearance of the mucosa was defined as a Mayo endoscopic subscore of 0 and was observed at Week 52 in 15% of patients in the XELJANZ 5 mg twice daily group and 17% of patients in the XELJANZ 10 mg twice daily group compared to 4% of placebo patients.

Open-label Extension Study (Study UC-IV [NCT01470612])

In Study UC-IV, 914 patients were treated of which 156 received 5 mg twice daily and 758 received 10 mg twice daily.

Of the 905 patients who were assigned to XELJANZ 10 mg twice daily in the 8-week induction studies (Study UC-I or Study UC-II), 322 patients completed the induction studies but did not achieve clinical response. Of these 322 patients, 291 continued to receive XELJANZ 10 mg twice daily (unblinded) and had available data after an additional 8 weeks in Study UC-IV. After 8 additional weeks (a total of 16 weeks treatment), 148 patients achieved clinical response, and 25 patients achieved remission (based on central endoscopy read). Among those 143 patients who achieved clinical response by 16 weeks and had available data at Week 52, 66 patients achieved remission (based on local endoscopy read) after continued treatment with XELJANZ 10 mg twice daily for 52 weeks.

14.5 Polyarticular Course Juvenile Idiopathic Arthritis

The efficacy of XELJANZ/XELJANZ Oral Solution for pcJIA was assessed in Study pcJIA-I (NCT02592434), a 44-week, two-part study (consisting of an 18-week, open-label, run-in phase, followed by a 26-week double-blind, placebo-controlled, randomized withdrawal phase) in patients 2 years to 17 years of age with active RF negative polyarthritis, RF positive polyarthritis, extended oligoarthritis, and systemic JIA without systemic manifestations who had an inadequate response or intolerance to at least one DMARD which could have included MTX or biologic agents; the study also included patients ages 2 years to 17 years of age with active juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA) who had an inadequate response to NSAIDs.

Patients received XELJANZ/XELJANZ Oral Solution (dosed at 5 mg twice daily or body weight-based equivalent twice daily) for 18 weeks (run-in phase) followed by randomization to either XELJANZ/XELJANZ Oral Solution (dosed at 5 mg twice daily or body weight-based equivalent twice daily) or placebo for 26 weeks (double-blind phase). Only patients who achieved at least a JIA ACR30 response at the end of the run-in phase were randomized (1:1) to the double-blind phase. Treatment with a stable dose of MTX was permitted but was not required during the study. Concurrent use of biologics or DMARDs other than MTX was not permitted in the study.

A total of 225 JIA patients (56 male and 169 female) with active polyarthritis were enrolled in the run-in phase including RF negative (104), RF positive (39), extended oligoarthritis (28), systemic JIA without systemic manifestations (13), JPsA (20), and ERA (21). Patients had a mean (SD) disease duration of 3.8 ± 3.5 years, and a mean (SD) number of active joints of 12.2 ± 8.1.

Of the 225 patients, 173 (76.9%) patients achieved JIA ACR30 response at Week 18 and were randomized into the double-blind phase to either active XELJANZ/XELJANZ Oral Solution (n=88) or placebo (n=85). At the conclusion of the 18-week, open-label, run-in phase, pediatric ACR 30/50/70 responses were 77%, 70%, and 49%, respectively.

In both the run-in and double-blind phases, approximately one-third of the patients were taking concomitant oral corticosteroids, and approximately two-thirds were taking concomitant MTX.

The primary endpoint was the occurrence of disease flare at Week 44 relative to the double-blind phase baseline at Week 18. Disease flare was defined (according to Pediatric Rheumatology Collaborative Study Group (PRCSG)/Pediatric Rheumatology International Trials Organization (PRINTO) Disease Flare criteria) as worsening of ≥30% in 3 or more of the 6 JIA core response variables with no more than 1 of the remaining JIA core response variables improving by ≥30%.

XELJANZ/XELJANZ Oral Solution treated patients experienced significantly fewer disease flares at Week 44 compared to placebo-treated patients (31% [27/88] vs. 55% [47/85]; difference in proportions -25% [95% CI: -39%, -10%]; p=0.0007). The occurrence of disease flare by visit in Study pcJIA-I is shown in Figure 7.

Figure 7: Occurrence of Disease Flare by Visit in the Double-Blind Phase in Study pcJIA-I

BID = twice daily; SE = standard error; N = total number of subjects.
The 26-week double-blind phase is from Week 18 through Week 44 on and after randomization day.

14.6 Safety Study

A randomized open-label trial (RA Safety Study 1; NCT02092467) was conducted to evaluate safety with XELJANZ at two doses, 5 mg twice daily (N=1455) and 10 mg twice daily (N=1456), versus the TNF-blocker control (N=1451) in RA patients 50 years of age and older with at least one cardiovascular risk factor. The co-primary endpoints were adjudicated MACE (defined as cardiovascular death, non-fatal MI, and non-fatal stroke) and adjudicated malignancy (excluding non-melanoma skin cancer); the study was designed to exclude a prespecified risk margin of 1.8 for the hazard ratio of combined XELJANZ regimens versus the TNF-blocker control for each co-primary endpoint. An independent committee conducted a blinded evaluation of the co-primary endpoints according to predefined criteria (adjudication). The study was event driven and patients were followed until a sufficient number of primary outcome events accrued. Other endpoints included mortality, serious infections, and thromboembolic events. The median on-study follow-up time was 4.0 years.

The mean age of the population was 61 years (range: 50 to 88 years). Most patients were female (78%) and Caucasian (77%). Patients had a diagnosis of RA for a mean of 10 years, and a median swollen and tender joint count of 11 and 15 respectively. Cardiovascular risk factors included cigarette smoking (current or past) (48%), hypertension (66%), high density lipoprotein < 40 mg/dL (12%), diabetes mellitus (17%), family history of premature coronary heart disease (15%), extra-articular disease associated with RA (37%), and history of coronary artery disease (11%).

The non-inferiority criterion was not met for the primary comparison of the combined tofacitinib doses to TNF blockers since the upper limit of the 95% CI exceeded the pre-specified non-inferiority criterion of 1.8 (for MACE, the upper limit of the 95% CI was 1.94; for malignancies excluding NMSC, the upper limit of the 95% CI was 2.09).

Table 21 shows the study results for each of the co-primary endpoints, and other endpoints. There was an increased risk of death, MACE, malignancies, serious infections, and thromboembolic events associated with both doses of XELJANZ.

Table 21: Results of RA Safety Study 1
Endpoint	XELJANZ 5 mg Twice Daily N=1455 PY=5490	XELJANZ 10 mg Twice Daily N=1456 PY=5298	TNF Blocker N=1451 PY=5468
Note: XELJANZ 10 mg twice daily was discontinued by the Data Monitoring Committee due to safety concerns, and ongoing patients switched from XELJANZ 10 mg to XELJANZ 5 mg. The column "XELJANZ 10 mg Twice Daily" includes all events and follow-up for patients randomized to XELJANZ 10 mg twice daily.A XELJANZ/XELJANZ Oral Solution 10 mg twice daily (or a XELJANZ XR 22 mg once daily) dosage is not recommended for the treatment of RA or PsA [see Dosage and Administration (2.2)]. N indicates number of patients; n indicates number of patients with events. IR indicates incidence rate per 100 person-year (PY). NMSC: Non-melanoma Skin Cancer; MACE: Major Adverse Cardiac Events; HR: Hazard Ratio; DVT: Deep Vein Thrombosis; PE: Pulmonary Embolism; VTE: Venous Thromboembolism, first occurrence of a VTE, defined as the composite of adjudicated DVT and adjudicated PE; ATE: Arterial Thromboembolism; TE: Thromboembolism, first occurrence of a TE, defined as the composite of adjudicated VTE and unadjudicated ATE.
* HR (95%) CI for XELJANZ vs. TNF Blocker (Univariate Cox Proportional Hazard Model). † MI and Stroke include fatal and non-fatal events. ‡ Data and analyses for Malignancies excluding NMSC for current and ex-smokers are included. There were 720 current and ex-smokers randomized to XELJANZ 5 mg, 704 to XELJANZ 10 mg, and 679 to TNF blockers.
MACE, n [IR]	50 [0.91]	59 [1.11]	43 [0.79]
HR (95% CI)*	1.16 (0.77, 1.74)	1.41 (0.95, 2.10)
MI,† n [IR]	20 [0.36]	21 [0.39]	11 [0.20]
HR (95% CI)*	1.81 (0.87, 3.79)	1.97 (0.95, 4.09)
Stroke,† n [IR]	18 [0.33]	21 [0.39]	20 [0.36]
HR (95% CI)*	0.89 (0.47, 1.69)	1.08 (0.59, 2.00)
Cardiovascular Death, n [IR]	18 [0.32]	25 [0.47]	15 [0.27]
HR (95% CI)*	1.20 (0.60, 2.37)	1.71 (0.90, 3.24)
Malignancies Excl. NMSC, n [IR]	62 [1.13]	60 [1.13]	42 [0.77]
HR (95% CI)*	1.47 (1.00, 2.18)	1.48 (1.00, 2.19)
Malignancies Excl. NMSC (among current and past smokers)‡	41 [1.53]	48 [1.91]	25 [0.99]
HR (95% CI)*	1.55 (0.94, 2.55)	1.94 (1.19, 3.14)
All Death	49 [0.88]	66 [1.23]	38 [0.69]
HR (95% CI)*	1.29 (0.84, 1.96)	1.79 (1.20, 2.66)
Serious Infections	155 [2.95]	184 [3.65]	133 [2.52]
HR (95% CI)*	1.17 (0.93, 1.47)	1.44 (1.15, 1.80)
DVT	12 [0.22]	15 [0.28]	9 [0.16]
HR (95% CI)*	1.33 (0.56, 3.15)	1.72 (0.75, 3.92)
PE	10 [0.18]	26 [0.49]	3 [0.05]
HR (95% CI)*	3.32 (0.91, 12.08)	8.95 (2.71, 29.56)
VTE	18 [0.33]	36 [0.68]	12 [0.22]
HR (95% CI)*	1.50 (0.72, 3.10)	3.10 (1.61, 5.96)
ATE	51 [0.93]	55 [1.04]	45 [0.83]
HR (95% CI)*	1.13 (0.76, 1.69)	1.26 (0.85, 1.87)
TE	67 [1.23]	86 [1.65]	56 [1.03]
HR (95% CI)*	1.19 (0.84, 1.70)	1.60 (1.14, 2.23)

Lymphomas and lung cancers, which are a subset of all malignancies in RA Safety Study 1, were observed at a higher rate in patients treated with XELJANZ 5 mg twice a day and XELJANZ 10 mg twice a day compared to those treated with TNF blockers. Lymphoma was reported for 4 patients receiving XELJANZ 5 mg twice a day, 6 patients receiving XELJANZ 10 mg twice a day, and 1 patient receiving TNF blockers (Incidence Rate [IR] of 0.07, 0.11, and 0.02 per 100 patient-years, respectively). Among current and past smokers, lung cancer was reported for 13 patients receiving XELJANZ 5 mg twice a day, 15 patients receiving XELJANZ 10 mg twice a day, and 7 patients receiving TNF blockers (IR of 0.48, 0.59, and 0.27 per 100 patient-years, respectively).

A XELJANZ/XELJANZ Oral Solution 10 mg twice daily (or a XELJANZ XR 22 mg once daily) dosage is not recommended for the treatment of RA or PsA [see Dosage and Administration (2.2)].

Find XELJANZ / XELJANZ XR medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

XELJANZ / XELJANZ XR Quick Finder

Prescribing Information

Download Prescribing Information

Health Professional Information

Clinical Studies

14 CLINICAL STUDIES

14.1 Rheumatoid Arthritis

Confirmatory Trials

Clinical Response

Table 9: Proportion of Patients with an ACR Response
	Percent of Patients
	Monotherapy in Nonbiologic or Biologic DMARD Inadequate Responders*		MTX Inadequate Responders†		TNF Blocker Inadequate Responders‡
	Study I		Study IV		Study V
N§	PBO	XELJANZ 5 mg Twice Daily	PBO + MTX	XELJANZ 5 mg Twice Daily + MTX	PBO + MTX	XELJANZ 5 mg Twice Daily + MTX
	122	243	160	321	132	133
* Inadequate response to at least one DMARD (biologic or nonbiologic) due to lack of efficacy or toxicity. † Inadequate response to MTX defined as the presence of sufficient residual disease activity to meet the entry criteria. ‡ Inadequate response to a least one TNF blocker due to lack of efficacy and/or intolerance. § N is number of randomized and treated patients. ¶ NA Not applicable, as data for placebo treatment is not available beyond 3 months in Studies I and V due to placebo advancement.
ACR20
Month 3	26%	59%	27%	55%	24%	41%
Month 6	NA¶	69%	25%	50%	NA	51%
ACR50
Month 3	12%	31%	8%	29%	8%	26%
Month 6	NA	42%	9%	32%	NA	37%
ACR70
Month 3	6%	15%	3%	11%	2%	14%
Month 6	NA	22%	1%	14%	NA	16%

Table 10: Proportion of Patients with DAS28-4(ESR) Less Than 2.6 with Number of Residual Active Joints
	Study IV
DAS28-4(ESR) Less Than 2.6	Placebo + MTX	XELJANZ 5 mg Twice Daily + MTX
	160	321
Proportion of responders at Month 6 (n)	1% (2)	6% (19)
Of responders, proportion with 0 active joints (n)	50% (1)	42% (8)
Of responders, proportion with 1 active joint (n)	0	5% (1)
Of responders, proportion with 2 active joints (n)	0	32% (6)
Of responders, proportion with 3 or more active joints (n)	50% (1)	21% (4)

The results of the components of the ACR response criteria for Study RA-IV are shown in Table 11. Similar results were observed for XELJANZ in Studies RA-I, II, III, V, and VI.

Table 11: Components of ACR Response at Month 3
	Study IV
	XELJANZ 5 mg Twice Daily + MTX		Placebo + MTX
	N=321		N=160
Component (mean) *	Baseline	Month 3*	Baseline	Month 3*
* Data shown is mean (Standard Deviation) at Month 3. † Visual analog scale: 0 = best, 100 = worst. ‡ Health Assessment Questionnaire Disability Index: 0 = best, 3 = worst; 20 questions; categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.
Number of tender joints (0–68)	24 (14)	13 (14)	23 (13)	18 (14)
Number of swollen joints (0–66)	14 (8)	6 (8)	14 (9)	10 (9)
Pain†	58 (23)	34 (23)	55 (24)	47 (24)
Patient global assessment†	58 (24)	35 (23)	54 (23)	47 (24)
Disability index (HAQ-DI)‡	1.41 (0.68)	0.99 (0.65)	1.32 (0.67)	1.19 (0.68)
Physician global assessment†	59 (16)	30 (19)	56 (18)	43 (22)
CRP (mg/L)	15.3 (19.0)	7.1 (19.1)	13.7 (14.9)	14.6 (18.7)

The percent of ACR20 responders by visit for Study RA-IV is shown in Figure 4. Similar responses were observed for XELJANZ in Studies RA-I, II, III, V, and VI.

Figure 4: Percentage of ACR20 Responders by Visit for Study RA-IV

Radiographic Response

In the placebo plus MTX group, 74% of patients experienced no radiographic progression at Month 6 compared to 84% of patients treated with XELJANZ plus MTX 5 mg twice daily.

In the MTX group, 55% of patients experienced no radiographic progression at Month 6 compared to 73% of patients treated with XELJANZ 5 mg twice daily.

Table 12: Radiographic Changes at Months 6 and 12
* SD = Standard Deviation † Difference between least squares means XELJANZ minus placebo or MTX (95% CI = 95% confidence interval) ‡ Month 6 and Month 12 data are mean change from baseline.
	Study IV
	Placebo N=139 Mean (SD)*	XELJANZ 5 mg Twice Daily N=277 Mean (SD) *	XELJANZ 5 mg Twice Daily Mean Difference from Placebo† (CI)
mTSS‡
Baseline	33 (42)	31 (48)	-
Month 6	0.5 (2.0)	0.1 (1.7)	-0.3 (-0.7, 0.0)
	Study VI
	MTX N=166 Mean (SD)*	XELJANZ 5 mg Twice Daily N=346 Mean (SD) *	XELJANZ 5 mg Twice Daily Mean Difference from MTX† (CI)
mTSS‡
Baseline	17 (29)	20 (40)	-
Month 6	0.8 (2.7)	0.2 (2.3)	-0.7 (-1.0, -0.3)
Month 12	1.3 (3.7)	0.4 (3.0)	-0.9 (-1.4, -0.4)

Physical Function Response

Other Health-Related Outcomes

14.2 Psoriatic Arthritis

Clinical Response

Table 13: Proportion of Patients with an ACR Response in Study PsA-I* [Nonbiologic DMARD Inadequate Responders (TNF Blocker-Naïve)]
Treatment Group	Placebo	XELJANZ 5 mg Twice Daily
N†	105	107
	Response Rate	Response Rate	Difference (%) 95% CI from Placebo
Subjects with missing data were treated as non-responders.
* Subjects received one concomitant nonbiologic DMARD. † N is number of randomized and treated patients.
Month 3
ACR20	33%	50%	17.1 (4.1, 30.2)
ACR50	10%	28%	18.5 (8.3, 28.7)
ACR70	5%	17%	12.1 (3.9, 20.2)

Table 14: Proportion of Patients with an ACR Response in Study PsA-II* (TNF Blocker Inadequate Responders)
Treatment Group	Placebo	XELJANZ 5 mg Twice Daily
N†	131	131
	Response Rate	Response Rate	Difference (%) 95% CI from Placebo
Subjects with missing data were treated as non-responders.
* Subjects received one concomitant nonbiologic DMARD. † N is number of randomized and treated patients.
Month 3
ACR20	24%	50%	26.0 (14.7, 37.2)
ACR50	15%	30%	15.3 (5.4, 25.2)
ACR70	10%	17%	6.9 (-1.3, 15.1)

Improvements from baseline in the ACR response criteria components for both studies are shown in Table 15.

Table 15: Components of ACR Response at Baseline and Month 3 in Studies PsA-I and PsA-II
	Nonbiologic DMARD Inadequate Responders (TNF Blocker-Naïve)		TNF Blocker Inadequate Responders
	Study PsA-I*		Study PsA-II*
Treatment Group	Placebo	XELJANZ 5 mg Twice Daily	Placebo	XELJANZ 5 mg Twice Daily
N at Baseline	105	107	131	131
* Subjects received one concomitant nonbiologic DMARD. † Data shown are mean value at baseline and at Month 3. ‡ Visual analog scale (VAS): 0 = best, 100 = worst. § HAQ-DI = Health Assessment Questionnaire – Disability Index: 0 = best, 3 = worst; 20 questions; categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.
ACR Component†
Number of tender/painful joints (0–68)
Baseline	20.6	20.5	19.8	20.5
Month 3	14.6	12.2	15.1	11.5
Number of swollen joints (0–66)
Baseline	11.5	12.9	10.5	12.1
Month 3	7.1	6.3	7.7	4.8
Patient assessment of arthritis pain‡
Baseline	53.2	55.7	54.9	56.4
Month 3	44.7	34.7	48.0	36.1
Patient global assessment of arthritis‡
Baseline	53.9	54.7	55.8	57.4
Month 3	44.4	35.5	49.2	36.9
HAQ-DI§
Baseline	1.11	1.16	1.25	1.26
Month 3	0.95	0.81	1.09	0.88
Physician's Global Assessment of Arthritis‡
Baseline	53.8	54.6	53.7	53.5
Month 3	35.4	29.5	36.4	27.0
CRP (mg/L)
Baseline	10.4	10.5	12.1	13.8
Month 3	8.6	4.0	11.4	7.7

BID=twice daily; SE=standard error.
Subjects with missing data were treated as non-responders.

*: Subjects received one concomitant nonbiologic DMARD.

Figure 5: Percentage of ACR20 Responders by Visit Through Month 3 in Study PsA-I*

In patients with active psoriatic arthritis evidence of benefit in enthesitis and dactylitis was observed with XELJANZ treatment.

Physical Function

Table 16: Change from Baseline in HAQ-DI in Studies PsA-I and PsA-II
	Least Squares Mean Change from Baseline In HAQ-DI at Month 3
	Nonbiologic DMARD Inadequate Responders* (TNF Blocker-Naïve)		TNF Blocker Inadequate Responders†
	Study PsA-I‡		Study PsA-II‡
Treatment Group	Placebo	XELJANZ 5 mg Twice Daily	Placebo	XELJANZ 5 mg Twice Daily
N§	104	107	131	129
* Inadequate response to at least one nonbiologic DMARD due to lack of efficacy and/or intolerability. † Inadequate response to at least one TNF blocker due to lack of efficacy and/or intolerability. ‡ Subjects received one concomitant nonbiologic DMARD. § N is the total number of subjects in the statistical analysis.
LSM Change from Baseline	-0.18	-0.35	-0.14	-0.39
Difference from Placebo (95% CI)	-	-0.17 (-0.29, -0.05)	-	-0.25 (-0.38, -0.13)

Other Health-Related Outcomes

Radiographic Response

Treatment effect on inhibition of radiographic progression in psoriatic arthritis could not be established from the results of Study PsA-I.

14.3 Ankylosing Spondylitis

Confirmatory Trial (Study AS-I)

Clinical Response

Table 17: ASAS20 and ASAS40 Responses at Week 16, Study AS-I
	Placebo	XELJANZ 5 mg Twice Daily	Difference from Placebo (95% CI)
Abbreviations: CI = confidence interval; TNFi-IR = tumor necrosis factor inhibitor inadequate response.
* type I error-controlled. † p-value <0.0001.
All patients (N)	N=136	N=133
ASAS20 response*, %	29	56	27 (16, 38)†
ASAS40 response*, %	13	41	28 (18, 38)†
TNFi-IR patients (N)	N=30	N=29
ASAS20 response, %	17	41	25 (2, 47)
ASAS40 response, %	7	28	21 (2, 39)

The improvements in the components of the ASAS response and other measures of disease activity were higher in XELJANZ 5 mg twice daily compared to placebo as shown in Table 18.

Table 18: ASAS Components and Other Measures of Disease Activity at Week 16, Study AS-I
	Placebo (N=136)		XELJANZ 5 mg Twice Daily (N=133)
	Baseline (mean)	Week 16 (LSM change from Baseline)*	Baseline (mean)	Week 16 (LSM change from Baseline)*	Difference from Placebo (95% CI)*
LSM = least squares mean.
* Estimates are generated based on a mixed model for repeated measures using both on-treatment and off-treatment data. † Measured on a numerical rating scale with 0 = not active or no pain, 10 = very active or most severe pain. ‡ type I error-controlled. § p < 0.0001. ¶ Bath Ankylosing Spondylitis Functional Index measured on a numerical rating scale with 0 = easy and 10 = impossible. # Inflammation is the mean of two patient-reported stiffness self-assessments in BASDAI. Þ Bath Ankylosing Spondylitis Disease Activity Index total score. ß Bath Ankylosing Spondylitis Metrology Index. à High sensitivity C-reactive protein.
ASAS Components
– Patient Global Assessment of Disease Activity (0–10)†,‡	7.0	-1.0	6.9	-2.5	-1.5 (-2.00, -0.97)§
– Total spinal pain (0–10)†,‡	6.9	-1.1	6.9	-2.6	-1.5 (-2.00, -1.03)§
– BASFI (0–10)¶,‡	5.9	-0.8	5.8	-2.0	-1.2 (-1.64, -0.79)§
– Inflammation (0–10)#,‡	6.8	-1.1	6.6	-2.8	-1.7 (-2.13, -1.18)§
BASDAI ScoreÞ	6.5	-1.2	6.4	-2.6	-1.4 (-1.86, -0.98)§
BASMIß,‡	4.4	-0.1	4.5	-0.6	-0.5 (-0.66, -0.36)§
hsCRPà,‡ (mg/dL)	1.8	-0.1	1.6	-1.1	-0.9 (-1.17, -0.69)§

The percentage of patients achieving ASAS20 response by visit is shown in Figure 6.

Figure 6: ASAS20 Response Over Time Up to Week 16, Study AS-I

SE=standard error.
Patients with missing data were treated as non-responders.

Other Health-Related Outcomes

14.4 Ulcerative Colitis

Induction Trials (Study UC-I [NCT01465763] and Study UC-II [NCT01458951])

The efficacy results of Study UC-I and Study UC-II based on the centrally read endoscopy results are shown in Table 19.

Table 19: Proportion of Patients Meeting Primary and Key Secondary Efficacy Endpoints at Week 8 (Induction Study UC-I and Study UC-II, Central Endoscopy Read)
CI = Confidence interval; N = number of patients in the analysis set; TNF = tumor necrosis factor
* Remission was defined as clinical remission (a Mayo score ≤2 with no individual subscore >1) and rectal bleeding subscore of 0. † p-value <0.01, ‡ Prior TNF blocker failure was defined in this program as inadequate response, loss of response, or intolerance to TNF blocker therapy. § Patients in this group had failed one or more conventional therapies (corticosteroid, azathioprine, 6-mercaptopurine) but did not have history of prior failure of TNF blocker therapy. ¶ Improvement of endoscopic appearance of the mucosa was defined as Mayo endoscopy subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern). # p-value <0.001.
Study UC-I
Endpoint	Placebo	XELJANZ 10 mg Twice Daily	Treatment Difference versus Placebo (95% CI)
Remission at Week 8*
Total Population	N=122	N=476	10%† (4.3, 16.3)
	8%	18%
With Prior TNF Blocker Failure‡	N=64	N=243
	2%	11%
Without Prior TNF Blocker Failure§	N=58	N=233
	16%	26%
Improvement of endoscopic appearance of the mucosa at Week 8¶
Total Population	N=122	N=476	16%# (8.1, 23.4)
	16%	31%
With Prior TNF Blocker Failure‡	N=64	N=243
	6%	23%
Without Prior TNF Blocker Failure§	N=58	N=233
	26%	40%
Study UC-II
Endpoint	Placebo	XELJANZ 10 mg Twice Daily	Treatment Difference (95% CI)
Remission at Week 8*
Total Population	N=112	N=429	13%# (8.1, 17.9)
	4%	17%
With Prior TNF Blocker Failure‡	N=60	N=222
	0%	12%
Without Prior TNF Blocker Failure§	N=52	N=207
	8%	22%
Improvement of endoscopic appearance of the mucosa at Week 8¶
Total Population	N=112	N-429	17%# (9.5, 24.1)
	12%	28%
With Prior TNF Blocker Failure‡	N=60	N=222
	7%	22%
Without Prior TNF Blocker Failure§	N=52	N=207
	17%	36%

Clinical Response at Week 8

Clinical response was observed in 60% of patients treated with XELJANZ 10 mg twice daily compared to 33% of placebo patients in Study UC-I and 55% compared to 29% in Study UC-II.

Normalization of the Endoscopic Appearance of the Mucosa at Week 8

Rectal Bleeding and Stool Frequency

Decreases in rectal bleeding and stool frequency subscores were observed as early as Week 2 in patients treated with XELJANZ.

Maintenance Trial (Study UC-III [NCT01458574])

At baseline of Study UC-III:

179 (30%) patients were in remission
289 (49%) patients were receiving oral corticosteroids
265 (45%), 445 (75%), and 413 (70%) patients had previously failed or were intolerant to TNF blocker therapy, corticosteroids, and immunosuppressants, respectively.

The efficacy results of Study UC-III based on the centrally read endoscopy results are summarized in Table 20.

Table 20: Proportion of Patients Meeting Primary and Key Secondary Efficacy Endpoints in Maintenance Study UC-III (Central Endoscopy Read)
				Treatment Difference versus Placebo (95% CI)
Endpoint	Placebo	XELJANZ 5 mg Twice Daily	XELJANZ 10 mg Twice Daily	XELJANZ 5 mg Twice Daily	XELJANZ 10 mg Twice Daily
CI = Confidence interval; N = number of patients in the analysis set; TNF = tumor necrosis factor.
* Remission was defined as clinical remission (a Mayo score ≤2 with no individual subscore >1) and rectal bleeding subscore of 0. † p-value <0.0001. ‡ Prior TNF blocker failure was defined in this program as inadequate response, loss of response, or intolerance to TNF blocker therapy. § Patients in this group had failed one or more conventional therapies (corticosteroid, azathioprine, 6-mercaptopurine) but did not have history of prior failure of TNF blocker therapy. ¶ Improvement of endoscopic appearance of the mucosa was defined as Mayo endoscopy subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern). # Sustained corticosteroid-free remission was defined as being in remission and not taking corticosteroids for at least 4 weeks prior to the visit at both Week 24 and Week 52.
Remission at Week 52*
Total Population	N=198	N=198	N=197	23%† (15.3, 31.2)	30%† (21.4, 37.6)
	11%	34%	41%
With Prior TNF Blocker Failure‡	N=89	N=83	N=93
	11%	24%	37%
Without Prior TNF Blocker Failure§	N=109	N=115	N=104
	11%	42%	44%
Improvement of endoscopic appearance of the mucosa at Week 52¶
Total Population	N=198	N=198	N=197	24%† (16.0, 32.5)	33%† (24.2, 41.0)
	13%	37%	46%
With Prior TNF Blocker Failure‡	N=89	N=83	N=93
	12%	30%	40%
Without Prior TNF Blocker Failure§	N=109	N=115	N=104
	14%	43%	51%
Sustained corticosteroid-free remission at both Week 24 and Week 52 among patients in remission at baseline#
Total Population	N=59	N=65	N=55	30%† (17.4, 43.2)	42%† (27.9, 56.5)
	5%	35%	47%
With Prior TNF Blocker Failure‡	N=21	N=18	N=18
	5%	22%	39%
Without Prior TNF Blocker Failure§	N=38	N=47	N=37
	5%	40%	51%

Maintenance of Clinical Response

Maintenance of clinical response was observed in 52% in the XELJANZ 5 mg twice daily group and 62% in the XELJANZ 10 mg twice daily group compared to 20% of placebo patients.

Maintenance of Remission (Among Patients in Remission at Baseline)

Normalization of the Endoscopic Appearance of the Mucosa

Open-label Extension Study (Study UC-IV [NCT01470612])

In Study UC-IV, 914 patients were treated of which 156 received 5 mg twice daily and 758 received 10 mg twice daily.

14.5 Polyarticular Course Juvenile Idiopathic Arthritis

In both the run-in and double-blind phases, approximately one-third of the patients were taking concomitant oral corticosteroids, and approximately two-thirds were taking concomitant MTX.

Figure 7: Occurrence of Disease Flare by Visit in the Double-Blind Phase in Study pcJIA-I

BID = twice daily; SE = standard error; N = total number of subjects.
The 26-week double-blind phase is from Week 18 through Week 44 on and after randomization day.

14.6 Safety Study

Table 21: Results of RA Safety Study 1
Endpoint	XELJANZ 5 mg Twice Daily N=1455 PY=5490	XELJANZ 10 mg Twice Daily N=1456 PY=5298	TNF Blocker N=1451 PY=5468
Note: XELJANZ 10 mg twice daily was discontinued by the Data Monitoring Committee due to safety concerns, and ongoing patients switched from XELJANZ 10 mg to XELJANZ 5 mg. The column "XELJANZ 10 mg Twice Daily" includes all events and follow-up for patients randomized to XELJANZ 10 mg twice daily.A XELJANZ/XELJANZ Oral Solution 10 mg twice daily (or a XELJANZ XR 22 mg once daily) dosage is not recommended for the treatment of RA or PsA [see Dosage and Administration (2.2)]. N indicates number of patients; n indicates number of patients with events. IR indicates incidence rate per 100 person-year (PY). NMSC: Non-melanoma Skin Cancer; MACE: Major Adverse Cardiac Events; HR: Hazard Ratio; DVT: Deep Vein Thrombosis; PE: Pulmonary Embolism; VTE: Venous Thromboembolism, first occurrence of a VTE, defined as the composite of adjudicated DVT and adjudicated PE; ATE: Arterial Thromboembolism; TE: Thromboembolism, first occurrence of a TE, defined as the composite of adjudicated VTE and unadjudicated ATE.
* HR (95%) CI for XELJANZ vs. TNF Blocker (Univariate Cox Proportional Hazard Model). † MI and Stroke include fatal and non-fatal events. ‡ Data and analyses for Malignancies excluding NMSC for current and ex-smokers are included. There were 720 current and ex-smokers randomized to XELJANZ 5 mg, 704 to XELJANZ 10 mg, and 679 to TNF blockers.
MACE, n [IR]	50 [0.91]	59 [1.11]	43 [0.79]
HR (95% CI)*	1.16 (0.77, 1.74)	1.41 (0.95, 2.10)
MI,† n [IR]	20 [0.36]	21 [0.39]	11 [0.20]
HR (95% CI)*	1.81 (0.87, 3.79)	1.97 (0.95, 4.09)
Stroke,† n [IR]	18 [0.33]	21 [0.39]	20 [0.36]
HR (95% CI)*	0.89 (0.47, 1.69)	1.08 (0.59, 2.00)
Cardiovascular Death, n [IR]	18 [0.32]	25 [0.47]	15 [0.27]
HR (95% CI)*	1.20 (0.60, 2.37)	1.71 (0.90, 3.24)
Malignancies Excl. NMSC, n [IR]	62 [1.13]	60 [1.13]	42 [0.77]
HR (95% CI)*	1.47 (1.00, 2.18)	1.48 (1.00, 2.19)
Malignancies Excl. NMSC (among current and past smokers)‡	41 [1.53]	48 [1.91]	25 [0.99]
HR (95% CI)*	1.55 (0.94, 2.55)	1.94 (1.19, 3.14)
All Death	49 [0.88]	66 [1.23]	38 [0.69]
HR (95% CI)*	1.29 (0.84, 1.96)	1.79 (1.20, 2.66)
Serious Infections	155 [2.95]	184 [3.65]	133 [2.52]
HR (95% CI)*	1.17 (0.93, 1.47)	1.44 (1.15, 1.80)
DVT	12 [0.22]	15 [0.28]	9 [0.16]
HR (95% CI)*	1.33 (0.56, 3.15)	1.72 (0.75, 3.92)
PE	10 [0.18]	26 [0.49]	3 [0.05]
HR (95% CI)*	3.32 (0.91, 12.08)	8.95 (2.71, 29.56)
VTE	18 [0.33]	36 [0.68]	12 [0.22]
HR (95% CI)*	1.50 (0.72, 3.10)	3.10 (1.61, 5.96)
ATE	51 [0.93]	55 [1.04]	45 [0.83]
HR (95% CI)*	1.13 (0.76, 1.69)	1.26 (0.85, 1.87)
TE	67 [1.23]	86 [1.65]	56 [1.03]
HR (95% CI)*	1.19 (0.84, 1.70)	1.60 (1.14, 2.23)

A XELJANZ/XELJANZ Oral Solution 10 mg twice daily (or a XELJANZ XR 22 mg once daily) dosage is not recommended for the treatment of RA or PsA [see Dosage and Administration (2.2)].

Medication Guide

Health Professional Information

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985^*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5Pm ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.

XELJANZ / XELJANZ XR Clinical Studies

(tofacitinib)

14 CLINICAL STUDIES

14.1 Rheumatoid Arthritis

14.2 Psoriatic Arthritis

14.3 Ankylosing Spondylitis

14.4 Ulcerative Colitis

14.5 Polyarticular Course Juvenile Idiopathic Arthritis

14.6 Safety Study

Find XELJANZ / XELJANZ XR medical information:

Find XELJANZ / XELJANZ XR medical information:

XELJANZ / XELJANZ XR Quick Finder

Health Professional Information

Clinical Studies

14 CLINICAL STUDIES

14.1 Rheumatoid Arthritis

14.2 Psoriatic Arthritis

14.3 Ankylosing Spondylitis

14.4 Ulcerative Colitis

14.5 Polyarticular Course Juvenile Idiopathic Arthritis

14.6 Safety Study

Health Professional Information

{{section_name_patient}}

Resources

Didn’t find what you were looking for? Contact us.

Report Adverse Event